HRP20120558T1 - Kapa-selektivni antagonist opioidnih receptora - Google Patents

Kapa-selektivni antagonist opioidnih receptora Download PDF

Info

Publication number
HRP20120558T1
HRP20120558T1 HRP20120558AT HRP20120558T HRP20120558T1 HR P20120558 T1 HRP20120558 T1 HR P20120558T1 HR P20120558A T HRP20120558A T HR P20120558AT HR P20120558 T HRP20120558 T HR P20120558T HR P20120558 T1 HRP20120558 T1 HR P20120558T1
Authority
HR
Croatia
Prior art keywords
disorder
pharmaceutically acceptable
chosen
acceptable salt
compound according
Prior art date
Application number
HRP20120558AT
Other languages
English (en)
Croatian (hr)
Inventor
Nuria Diaz Buezo
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20120558T1 publication Critical patent/HRP20120558T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
HRP20120558AT 2008-01-22 2009-01-13 Kapa-selektivni antagonist opioidnih receptora HRP20120558T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (1)

Publication Number Publication Date
HRP20120558T1 true HRP20120558T1 (hr) 2012-10-31

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120558AT HRP20120558T1 (hr) 2008-01-22 2009-01-13 Kapa-selektivni antagonist opioidnih receptora

Country Status (32)

Country Link
US (2) US7709522B2 (OSRAM)
EP (1) EP2252581B1 (OSRAM)
JP (1) JP5345637B2 (OSRAM)
KR (1) KR101172170B1 (OSRAM)
CN (1) CN101925576B (OSRAM)
AR (1) AR070158A1 (OSRAM)
AU (1) AU2009206653B2 (OSRAM)
BR (1) BRPI0907382B8 (OSRAM)
CA (1) CA2713025C (OSRAM)
CO (1) CO6290644A2 (OSRAM)
CY (1) CY1113071T1 (OSRAM)
DK (1) DK2252581T3 (OSRAM)
DO (1) DOP2010000222A (OSRAM)
EA (1) EA017484B1 (OSRAM)
EC (1) ECSP10010365A (OSRAM)
ES (1) ES2388708T3 (OSRAM)
HR (1) HRP20120558T1 (OSRAM)
IL (1) IL206038A (OSRAM)
JO (1) JO2797B1 (OSRAM)
MA (1) MA32751B1 (OSRAM)
MX (1) MX2010007849A (OSRAM)
MY (1) MY163014A (OSRAM)
NZ (1) NZ586225A (OSRAM)
PE (1) PE20091317A1 (OSRAM)
PL (1) PL2252581T3 (OSRAM)
PT (1) PT2252581E (OSRAM)
SI (1) SI2252581T1 (OSRAM)
TN (1) TN2010000306A1 (OSRAM)
TW (1) TWI422369B (OSRAM)
UA (1) UA100715C2 (OSRAM)
WO (1) WO2009094260A1 (OSRAM)
ZA (1) ZA201003908B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201070876A1 (ru) * 2008-01-22 2011-04-29 Такеда Фармасьютикал Компани Лимитед Трициклические соединения, обладающие антагонистической активностью по отношению к кортикотропин-высвобождающему фактору, и содержащие их фармацевтические композиции
JO2797B1 (en) * 2008-01-22 2014-03-15 ايلي ليلي اند كومباني Selective opioid receptor antagonist kappa
US9345703B2 (en) 2011-09-15 2016-05-24 University Of Kansas Kappa opioid receptor effectors and uses thereof
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
JP6061948B2 (ja) 2011-12-09 2017-01-18 リサーチ トライアングル インスティテュート κオピオイド受容体アンタゴニストとしての1−置換4−アリールピペラジン
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
JP2016519161A (ja) * 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
CN110914262B (zh) 2017-03-17 2024-04-05 斯克里普斯研究所 κ阿片受体拮抗剂以及与其相关的产品和方法
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
WO2022234457A1 (en) 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
IL314176A (en) * 2022-01-10 2024-09-01 Janssen Pharmaceuticals Inc Compositions and methods for treating depression
US20250221960A1 (en) * 2022-01-10 2025-07-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
PE20242109A1 (es) * 2022-03-07 2024-10-28 Janssen Pharmaceuticals Inc Formas puras de aticaprant cristalino
CA3254546A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
CN1164590C (zh) * 1999-05-12 2004-09-01 弗·哈夫曼-拉罗切有限公司 咪唑二氮杂�衍生物
AU2001292164A1 (en) * 2000-10-05 2002-04-15 Hanns Mohler Selective anxiolytic therapeutic agents
EP1353665A4 (en) 2000-12-21 2004-05-06 Mclean Hospital Corp Treatment of depression
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
KR100865410B1 (ko) * 2002-03-28 2008-10-24 위시스 테크놀로지 파운데이션, 인크. 진정 및 운동실조 효과가 감소된 항불안제
ES2305491T3 (es) 2002-09-19 2008-11-01 Eli Lilly And Company Eteres de diarilo como antagonistas de receptores de opioides.
DE602004016127D1 (de) 2003-03-07 2008-10-09 Lilly Co Eli Antagonisten der opioidrezeptoren
ATE377589T1 (de) 2003-03-07 2007-11-15 Lilly Co Eli 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
CA2549009A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
EP1699783B1 (en) 2003-12-22 2012-07-25 Eli Lilly And Company Opioid receptor antagonists
WO2005090286A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
CA2559207A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
EP1730140B1 (en) 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
CA2557794A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
CA2558030A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
HRP20100113T1 (hr) 2006-04-04 2010-04-30 Emodys Gmbh Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja
WO2008021851A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
CA2662766C (en) 2006-09-08 2011-08-09 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
JO2797B1 (en) * 2008-01-22 2014-03-15 ايلي ليلي اند كومباني Selective opioid receptor antagonist kappa

Also Published As

Publication number Publication date
CN101925576B (zh) 2013-02-06
ECSP10010365A (es) 2010-08-31
EA201070877A1 (ru) 2010-12-30
US20090186873A1 (en) 2009-07-23
AU2009206653B2 (en) 2013-07-18
EA017484B1 (ru) 2012-12-28
US8173695B2 (en) 2012-05-08
HK1146822A1 (en) 2011-07-15
MY163014A (en) 2017-07-31
TWI422369B (zh) 2014-01-11
UA100715C2 (ru) 2013-01-25
MX2010007849A (es) 2010-08-09
US20100197669A1 (en) 2010-08-05
DK2252581T3 (da) 2012-07-16
PL2252581T3 (pl) 2012-10-31
TW200936129A (en) 2009-09-01
DOP2010000222A (es) 2015-11-15
NZ586225A (en) 2012-05-25
IL206038A0 (en) 2010-11-30
EP2252581A1 (en) 2010-11-24
BRPI0907382A2 (pt) 2015-07-21
AU2009206653A1 (en) 2009-07-30
KR101172170B1 (ko) 2012-08-07
BRPI0907382B8 (pt) 2021-05-25
JP2011524850A (ja) 2011-09-08
PT2252581E (pt) 2012-08-31
MA32751B1 (fr) 2011-11-01
ZA201003908B (en) 2011-11-30
US7709522B2 (en) 2010-05-04
CY1113071T1 (el) 2016-04-13
ES2388708T3 (es) 2012-10-17
WO2009094260A1 (en) 2009-07-30
CA2713025C (en) 2012-12-04
TN2010000306A1 (en) 2011-11-11
JO2797B1 (en) 2014-03-15
KR20100095639A (ko) 2010-08-31
IL206038A (en) 2013-11-28
SI2252581T1 (sl) 2012-09-28
CN101925576A (zh) 2010-12-22
BRPI0907382B1 (pt) 2020-03-10
CA2713025A1 (en) 2009-07-30
AR070158A1 (es) 2010-03-17
CO6290644A2 (es) 2011-06-20
PE20091317A1 (es) 2009-09-03
EP2252581B1 (en) 2012-06-20
JP5345637B2 (ja) 2013-11-20

Similar Documents

Publication Publication Date Title
HRP20120558T1 (hr) Kapa-selektivni antagonist opioidnih receptora
JP2011524850A5 (OSRAM)
JP2011148799A5 (OSRAM)
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
FI3406609T3 (fi) Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
AR079198A1 (es) Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina
NO20071300L (no) Trifluormetylsubstituerte benzamider som kinaseinhibitorer.
JP2007519754A5 (OSRAM)
HRP20150925T1 (hr) Agensi koji induciraju apoptozu za lijeäśenje raka te imunih i autoimunih bolesti
NZ603364A (en) Inhibitors of arginase and their therapeutic applications
EA200971046A1 (ru) Новые соли пиперазина в качестве d/d-антагонистов
NZ617334A (en) Cyclopropyl amine derivatives
RU2018112993A (ru) Соединения и способы для ингибирования JAK
WO2012101065A3 (en) Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors
MY149005A (en) Amine salts of a crth2 antagonist
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
SI2185155T1 (en) Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors
RU2016149804A (ru) Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой
HRP20171824T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A
HRP20151003T1 (hr) Novi spojevi kao ligandi receptora histamina h3
HRP20110333T1 (hr) 4[(3-fluorfenoksi)fenilmetil]piperidin-metansulfonat: upotreba, postupci sinteze i farmaceutski pripravci
BR112015012752A2 (pt) derivados de amino ciclo butano, o respectivo processo de preparo e a respectiva utilização a título de medicamentos
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister